To boost NK and CTL responses in NSCLC patients after first-line chemotherapy, exosomes derived from IFN-γ-matured DCs loaded with MHC-restricted cancer antigens were tested in a recent phase II clinical trial [102]. This evidence concerns the gene IFNG and cancer.